Pomalidomide-PEG2-OH is a high-purity E3 Ligase Ligand-Linker Conjugate designed for PROTAC (Proteolysis Targeting Chimera) drug discovery and development. This compound features pomalidomide, a well-characterized cereblon (CRBN) binding ligand, coupled with a PEG2 (polyethylene glycol dimethyl ether) linker terminating in a hydroxyl group (-OH). The PEG2 linker provides optimal flexibility and solubility, facilitating efficient conjugation to target protein ligands in PROTAC synthesis. In the PROTAC mechanism, the E3 ligase ligand (such as pomalidomide) recruits CRBN, bringing it into proximity with the protein of interest (POI) for ubiquitination and subsequent proteasomal degradation. Pomalidomide-PEG2-OH is a valuable chemical building block for generating bifunctional molecules that promote targeted protein degradation, a promising therapeutic approach for a broad range of biological targets including oncogenic proteins, transcription factors, and other disease-related proteins previously considered "undruggable". Ideal for medicinal chemistry, chemical biology, and early-stage drug discovery, Pomalidomide-PEG2-OH enables researchers to custom-design PROTACs or molecular glues for novel protein degradation strategies. This product is supplied as a chemically stable reagent, ready for conjugation and structure-activity relationship (SAR) research applications in academia or industry.
Structure of 2143097-10-1
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Pomalidomide-PEG2-OH is a cutting-edge E3 ligase ligand-linker conjugate designed to facilitate the development of PROTACs (Proteolysis Targeting Chimeras). This compound integrates pomalidomide, a well-characterized cereblon (CRBN) E3 ligase ligand, with a PEG2 (polyethylene glycol) linker terminated with a hydroxyl (-OH) group, providing versatile functionality for downstream chemical conjugation. As PROTACs continue to revolutionize targeted protein degradation, linker-payload conjugates like Pomalidomide-PEG2-OH are essential building blocks in the creation of next-generation therapeutics.
Mechanism
Pomalidomide-PEG2-OH operates as an E3 ligase-recruiting module in bifunctional molecules such as PROTACs. Pomalidomide selectively binds to the CRBN substrate receptor within the CUL4 E3 ubiquitin ligase complex. The PEG2 linker provides optimal spatial flexibility, allowing the terminal -OH group to be further coupled to a ligand that binds the target protein of interest (POI). Once a PROTAC is assembled using this conjugate, it enables the simultaneous recruitment of the E3 ligase and the POI, facilitating ubiquitination and subsequent proteasomal degradation of the target.
Applications
Pomalidomide-PEG2-OH finds widespread use in the design and synthesis of PROTAC molecules for targeted protein degradation. Researchers use this conjugate to create custom PROTACs against disease-relevant targets in oncology, neurology, and beyond. Its structure ensures reliable CRBN engagement while providing a functional handle for linking novel target ligands. The product streamlines the drug discovery process by simplifying PROTAC construction, supporting SAR (Structure-Activity Relationship) studies, and enabling rapid prototyping of degrader compounds in biological assays.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.